JP Morgan Chase’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-26,870
| Closed | -$131K | – | 7093 |
|
|
2025
Q1 | $131K | Sell |
26,870
-23,856
| -47% | -$143K | ﹤0.01% | 5436 |
|
|
2024
Q4 | $423K | Buy |
50,726
+19,633
| +63% | +$172K | ﹤0.01% | 5129 |
|
|
2024
Q3 | $323K | Sell |
31,093
-695
| -2% | -$11.6K | ﹤0.01% | 5161 |
|
|
2024
Q2 | $626K | Sell |
31,788
-64,866
| -67% | -$1.3M | ﹤0.01% | 4558 |
|
|
2024
Q1 | $2.47M | Buy |
96,654
+8,862
| +10% | +$227K | ﹤0.01% | 3681 |
|
|
2023
Q4 | $2.42M | Buy |
87,792
+4,253
| +5% | +$259K | ﹤0.01% | 3688 |
|
|
2023
Q3 | $5.08M | Sell |
83,539
-4,677
| -5% | -$329K | ﹤0.01% | 2841 |
|
|
2023
Q2 | $5.8M | Buy |
88,216
+25,968
| +42% | +$1.9M | ﹤0.01% | 2748 |
|
|
2023
Q1 | $3.96M | Sell |
62,248
-2,404
| -4% | -$275K | ﹤0.01% | 3008 |
|
|
2022
Q4 | $8.95M | Buy |
64,652
+3,308
| +5% | +$466K | ﹤0.01% | 2361 |
|
|
2022
Q3 | $7.77M | Sell |
61,344
-23,930
| -28% | -$2.71M | ﹤0.01% | 2364 |
|
|
2022
Q2 | $7.06M | Sell |
85,274
-7,953
| -9% | -$617K | ﹤0.01% | 2462 |
|
|
2022
Q1 | $9.04M | Sell |
93,227
-17,569
| -16% | -$2.32M | ﹤0.01% | 2472 |
|
|
2021
Q4 | $22.1M | Sell |
110,796
-38,408
| -26% | -$9.06M | ﹤0.01% | 1741 |
|
|
2021
Q3 | $36.9M | Buy |
149,204
+23,410
| +19% | +$6.69M | ﹤0.01% | 1339 |
|
|
2021
Q2 | $52.1M | Buy |
125,794
+41,268
| +49% | +$16.3M | 0.01% | 1204 |
|
|
2021
Q1 | $33M | Buy |
84,526
+35,327
| +72% | +$17.4M | ﹤0.01% | 1387 |
|
|
2020
Q4 | $27.6M | Buy |
49,199
+33,049
| +205% | +$20.9M | ﹤0.01% | 1398 |
|
|
2020
Q3 | $11.5M | Buy |
16,150
+1,526
| +10% | +$1.19M | ﹤0.01% | 1927 |
|
|
2020
Q2 | $11.6M | Buy |
14,624
+3,678
| +34% | +$2.77M | ﹤0.01% | 1782 |
|
|
2020
Q1 | $6.52M | Buy |
10,946
+3,304
| +43% | +$3.22M | ﹤0.01% | 2058 |
|
|
2019
Q4 | $8.69M | Buy |
7,642
+2,480
| +48% | +$2.7M | ﹤0.01% | 2228 |
|
|
2019
Q3 | $6.14M | Buy |
5,162
+674
| +15% | +$1.03M | ﹤0.01% | 2518 |
|
|
2019
Q2 | $7.21M | Sell |
4,488
-206
| -4% | -$356K | ﹤0.01% | 2355 |
|
|
2019
Q1 | $9.57M | Buy |
4,694
+823
| +21% | +$1.45M | ﹤0.01% | 2096 |
|
|
2018
Q4 | $4.97M | Sell |
3,871
-102
| -3% | -$156K | ﹤0.01% | 2579 |
|
|
2018
Q3 | $7.51M | Sell |
3,973
-4,934
| -55% | -$10.2M | ﹤0.01% | 2433 |
|
|
2018
Q2 | $18.1M | Sell |
8,907
-1,319
| -13% | -$3.01M | ﹤0.01% | 1672 |
|
|
2018
Q1 | $22.6M | Buy |
10,226
+5,012
| +96% | +$12.7M | ﹤0.01% | 1428 |
|
|
2017
Q4 | $12M | Buy |
5,214
+1,073
| +26% | +$2.18M | ﹤0.01% | 1973 |
|
|
2017
Q3 | $7.57M | Sell |
4,141
-125
| -3% | -$175K | ﹤0.01% | 2218 |
|
|
2017
Q2 | $5.8M | Sell |
4,266
-1,151
| -21% | -$1.39M | ﹤0.01% | 2379 |
|
|
2017
Q1 | $6.38M | Sell |
5,417
-6,801
| -56% | -$6.94M | ﹤0.01% | 2264 |
|
|
2016
Q4 | $9.77M | Buy |
12,218
+4,684
| +62% | +$3.72M | ﹤0.01% | 1925 |
|
|
2016
Q3 | $6.61M | Buy |
7,534
+954
| +14% | +$691K | ﹤0.01% | 2049 |
|
|
2016
Q2 | $3.69M | Buy |
6,580
+1,977
| +43% | +$1.12M | ﹤0.01% | 2474 |
|
|
2016
Q1 | $2.54M | Buy |
4,603
+302
| +7% | +$185K | ﹤0.01% | 2575 |
|
|
2015
Q4 | $3.58M | Sell |
4,301
-717
| -14% | -$716K | ﹤0.01% | 2424 |
|
|
2015
Q3 | $5.56M | Sell |
5,018
-4,504
| -47% | -$8.21M | ﹤0.01% | 2155 |
|
|
2015
Q2 | $20.8M | Sell |
9,522
-1,433
| -13% | -$2.92M | ﹤0.01% | 1389 |
|
|
2015
Q1 | $17.1M | Buy |
10,955
+450
| +4% | +$594K | ﹤0.01% | 1534 |
|
|
2014
Q4 | $12.5M | Buy |
10,505
+5,875
| +127% | +$3.93M | ﹤0.01% | 1792 |
|
|
2014
Q3 | $2.15M | Buy |
+4,630
| New | +$2.14M | ﹤0.01% | 2885 |
|
|
2013
Q4 | – | Sell |
-975
| Closed | -$341K | – | 4092 |
|
|
2013
Q3 | $341K | Buy |
+975
| New | +$362K | ﹤0.01% | 3813 |
|
Other funds holding BLUE
JP Morgan Chase's BLUE Position: Q2 2025 in Review
JP Morgan Chase sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 26,870 shares — an estimated $131K sold.
JP Morgan Chase first reported a position in BLUE in Q3 2013 and held it in 44 quarters. The position peaked at $52.1M in Q2 2021. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.
- JP Morgan Chase reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
- JP Morgan Chase sold 26,870 bluebird bio shares in Q2 2025, an estimated $131K.
- JP Morgan Chase first reported a position in bluebird bio in Q3 2013 and held it in 44 quarters.
- JP Morgan Chase's bluebird bio position peaked at $52.1M in Q2 2021.
- 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.
Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.